Kymab Group Limited, a Cambridge, UK-based monoclonal antibody biopharmaceutical group, received a $9m grant.
The Gates Foundation, which has also invested $30m in Kymab’s Series B and Series C financing, will provide the research and development grant funding over the next three years.
The grant will enable Kymab to to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV. The Foundation will have the rights to develop and distribute these products to low-income countries and Kymab will retain rights to commercialise the products in developed countries. This funding builds on Kymab’s established work, allowing the parties to further collaborate in the future.
Led by Dr. David Chiswell, CEO, and Professor Allan Bradley, Chief Technology Officer, Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ antibody platform.
Kymab, which has raised over US$220m of equity financing which includes $100m Series C financing, has been working with the Gates Foundation and its partners since 2014 on programs in diseases such as malaria, HIV, and Typhoid.